Form 4: Health Catalyst Director Receives RSU Award

Health Catalyst, Inc. Director Julie Larson-Green was awarded 4,588 restricted stock units, which vested on September 1, 2025.

Summary

• Julie Larson-Green, a Director of Health Catalyst, Inc. (HCAT), was granted 4,588 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of the Issuer's common stock per RSU.
• The award was made pursuant to the Issuer's 2019 Stock Option and Incentive Plan and in accordance with the Non-Employee Director Compensation Policy.
• 100% of these RSUs vested on September 1, 2025.
• Following this transaction, Ms. Larson-Green beneficially owns 115,839 shares of common stock directly.

Sentiment

Score: 7

Explanation: The filing reports a routine equity award to a director, which is a positive for aligning management interests with shareholders but not a significant market-moving event. It reflects standard corporate governance practices.

Positives

• The award of 4,588 restricted stock units to a director aligns her interests with long-term shareholder value.
• The vesting of these RSUs on September 1, 2025, represents a standard component of non-employee director compensation.

Future Outlook

The filing indicates a future vesting event for director compensation, reflecting ongoing equity-based incentives for board members.

Industry Context

Equity awards like Restricted Stock Units (RSUs) are a common form of compensation for non-employee directors in the technology and healthcare IT sectors, aligning their incentives with company performance and shareholder interests. This practice is standard across publicly traded companies to attract and retain qualified board members.

Stakeholder Impact

• Shareholders: The award aligns the director's interests with long-term shareholder value, potentially encouraging decisions that benefit the stock price.
• Employees: No direct impact on general employees is indicated by this director-specific compensation.
• Customers/Suppliers/Creditors: No direct impact is indicated.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a director, which is a standard practice for aligning interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions, as this specific filing is not a catalyst for a buy or sell decision.

Keywords

Health Catalyst, HCAT, Julie Larson-Green, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, SEC Form 4, Equity Award